CD8A and neoplasm: KCL-HO-1i also resulted in an increased proportion of CD8+ T-cells capable of expressing IFNγ within the TME, an effect that was further boosted when KCL-HO-1i was administered alongside 5-FU or gemcitabine (Figure 4F), where CD8+ T-cells could be found infiltrating the tumor (Figure 4G).